Skip to main content
Top

30-04-2024 | Liposarcoma | Case Report - Pathology

A case of dedifferentiated liposarcoma discovered due to an intrascrotal calcified ossification

Authors: Haruna Arai, Hirofumi Sogabe, Shinnosuke Morikawa, Osuke Arai, Ryuta Watanabe, Akira Ozawa, Akira I. Hida, Tokuhiro Iseda, Kenichi Kohashi, Yoshinao Oda

Published in: International Cancer Conference Journal

Login to get access

Abstract

Dedifferentiated liposarcoma is a rare cancer with a poor prognosis. A 52-year-old man presented with a chief complaint of a mass in his left scrotum. He came with suspected testicular tumor, but all the measured tumor markers were negative. Imaging test showed approximately 2 cm diameter mass accompanied by calcification with some substantial components between the testis and epididymis. Left high testicular resection was performed. The tumor had no continuity between the testis and epididymis, and the spermatic cord transection was negative. Pathological findings showed well differentiated fatty component and a dedifferentiated component around the trabecular bone-like tissue. We observed dedifferentiated dysmorphic cells mixed with fatty droplets of unequal size. Immunostaining led to the diagnosis of dedifferentiated liposarcoma. No additional postoperative therapy was performed. The possibility of dedifferentiated liposarcoma should be kept in mind even if mass is confined to the scrotum and consisted of calcification. In the case of an intrascrotal calcified mass with malignant perspective, radical surgery is highly recommended.
Literature
1.
2.
go back to reference Waters R, Horvai A, Greipp P et al (2019) Atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma in patients aged ≤40 years: a study of 116 patients. Histopathology 75:833–842CrossRefPubMed Waters R, Horvai A, Greipp P et al (2019) Atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma in patients aged ≤40 years: a study of 116 patients. Histopathology 75:833–842CrossRefPubMed
3.
go back to reference Ishibashi Y et al (2022) A case of dedifferentiated liposarcoma of the spermatic cord. Acta Urol 68:17–21 Ishibashi Y et al (2022) A case of dedifferentiated liposarcoma of the spermatic cord. Acta Urol 68:17–21
4.
go back to reference Kumada N et al (2020) A case of liposarcoma of the spermatic cord. Toyota J Med 29:62–66 Kumada N et al (2020) A case of liposarcoma of the spermatic cord. Toyota J Med 29:62–66
5.
go back to reference Takaoka N et al (2019) A case of dedifferentiated liposarcoma of the spermatic cord. Acta Urol 65:529–532 Takaoka N et al (2019) A case of dedifferentiated liposarcoma of the spermatic cord. Acta Urol 65:529–532
6.
go back to reference Tobiume M et al (2019) A case of dedifferentiated liposarcoma of the spermatic cord. Acta Urol 65:429–434 Tobiume M et al (2019) A case of dedifferentiated liposarcoma of the spermatic cord. Acta Urol 65:429–434
7.
go back to reference Shinohara M et al (2019) A case of dedifferentiated liposarcoma in the scrotum. J Urol Surg 32:307 Shinohara M et al (2019) A case of dedifferentiated liposarcoma in the scrotum. J Urol Surg 32:307
8.
go back to reference Ando T et al (2018) Dedifferentiated spermatic cord liposarcoma with macroscopic ossification. IJU 1:5–8 Ando T et al (2018) Dedifferentiated spermatic cord liposarcoma with macroscopic ossification. IJU 1:5–8
9.
go back to reference Oshikawa Y et al (2018) A case of liposarcoma in the scrotum in the very elderly. Nishi Nihon Hinyokika 80:305 Oshikawa Y et al (2018) A case of liposarcoma in the scrotum in the very elderly. Nishi Nihon Hinyokika 80:305
10.
go back to reference Tanaka S et al (2013) A case of dedifferentiated liposarcoma of the spermatic cord. J Urol Surg 26:754 Tanaka S et al (2013) A case of dedifferentiated liposarcoma of the spermatic cord. J Urol Surg 26:754
11.
go back to reference Akaihata H et al (2009) A case of liposarcoma occurring in the scrotum. Jpn J Urol 63:811–815 Akaihata H et al (2009) A case of liposarcoma occurring in the scrotum. Jpn J Urol 63:811–815
12.
go back to reference Evans HL et al (1979) Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol 3:507–523CrossRefPubMed Evans HL et al (1979) Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol 3:507–523CrossRefPubMed
13.
go back to reference Gondo T et al (2007) Retroperitoneal dedifferentiated liposarcoma: case report. Jpn J Urol 98:795–799CrossRef Gondo T et al (2007) Retroperitoneal dedifferentiated liposarcoma: case report. Jpn J Urol 98:795–799CrossRef
15.
go back to reference Livingston JA, Bugano D, Barbo A et al (2017) Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep 19:11836CrossRef Livingston JA, Bugano D, Barbo A et al (2017) Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep 19:11836CrossRef
16.
go back to reference Schöffski P, Chawla S, Maki RG et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387:1629–1637CrossRefPubMed Schöffski P, Chawla S, Maki RG et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387:1629–1637CrossRefPubMed
17.
go back to reference Demetri GD, Von Mehren M, Jones RL et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786–793CrossRefPubMed Demetri GD, Von Mehren M, Jones RL et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786–793CrossRefPubMed
18.
go back to reference Bauer TM, Gounder MM, Weise AM et al (2018) A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). J Clin Oncol 36:11514CrossRef Bauer TM, Gounder MM, Weise AM et al (2018) A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). J Clin Oncol 36:11514CrossRef
19.
go back to reference Nagae I et al (2007) A case of differentiated liposarcoma of the spermatic cord with widely infiltrative local recurrence. Jpn J Gastroenterol Surg 40:349–354CrossRef Nagae I et al (2007) A case of differentiated liposarcoma of the spermatic cord with widely infiltrative local recurrence. Jpn J Gastroenterol Surg 40:349–354CrossRef
Metadata
Title
A case of dedifferentiated liposarcoma discovered due to an intrascrotal calcified ossification
Authors
Haruna Arai
Hirofumi Sogabe
Shinnosuke Morikawa
Osuke Arai
Ryuta Watanabe
Akira Ozawa
Akira I. Hida
Tokuhiro Iseda
Kenichi Kohashi
Yoshinao Oda
Publication date
30-04-2024
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-024-00682-6
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine